Heart rhythm · 2026
Association of angiotensin receptor-neprilysin inhibitor duration with latent remodeling following implantable cardioverter defibrillator implantation.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Jooyeon, Oh Jaewon, Kim Daehoon, Yu Hee Tae, Lee Chan Joo, Kim Tae-Hoon, Uhm Jae-Sun, Kim Young Jin, Pak Hui-Nam, Joung Boyoung, Hong Yoo Jin, Kang Seok-Min
Аннотация
BACKGROUND: The optimal duration of angiotensin receptor-neprilysin inhibitor (ARNI) exposure before implantable cardioverter-defibrillator (ICD) implantation remains undefined. In nonischemic dilated cardiomyopathy (NIDCM), reverse remodeling may continue beyond device implantation. However, predictors of post-implant latent left ventricular reverse remodeling (LVRR) remain unclear.
OBJECTIVE: This study investigated the association between duration of pre-ICD ARNI therapy and latent LVRR in patients with NIDCM.
METHODS: Seventy-five patients with NIDCM (69.3% male, mean age 61 years) with LVEF of ≤35% and prior ARNI treatment before primary prevention ICD implantation were retrospectively analyzed. Latent LVRR was defined as an absolute ≥10% increase in LVEF with a final LVEF of ≥40% at 1-year post-implant. Multivariable logistic regression identified the predictors of latent LVRR.
RESULTS: At 1 year, 22 patients (29.3%) exhibited latent LVRR. Shorter duration from heart failure diagnosis (4.8 vs 30.1 months; odds ratio, 0.88, P = .007) and ARNI initiation (2.3 vs 7.2 months; odds ratio, 0.90, P = .029) to ICD implant were independently associated with latent LVRR. Cardiac magnetic resonance imaging analysis showed uniformly elevated fibrosis markers across groups, with no difference observed in native T1, T2, extracellular volume, or late gadolinium enhancement. Conventional variables, including age, sex, QRS duration, heart rate, and late gadolinium enhancement burden, were not predictive. Over a median follow-up of 33.8 months, ventricular arrhythmia incidence was comparable (9.1% vs 7.5%).
CONCLUSION: Shorter ARNI exposure before ICD implantation was independently associated with latent LVRR, highlighting the need for sufficient guideline-directed medical therapy to optimize reverse remodeling, whereas residual arrhythmic risk warrants continued ICD protection.
OBJECTIVE: This study investigated the association between duration of pre-ICD ARNI therapy and latent LVRR in patients with NIDCM.
METHODS: Seventy-five patients with NIDCM (69.3% male, mean age 61 years) with LVEF of ≤35% and prior ARNI treatment before primary prevention ICD implantation were retrospectively analyzed. Latent LVRR was defined as an absolute ≥10% increase in LVEF with a final LVEF of ≥40% at 1-year post-implant. Multivariable logistic regression identified the predictors of latent LVRR.
RESULTS: At 1 year, 22 patients (29.3%) exhibited latent LVRR. Shorter duration from heart failure diagnosis (4.8 vs 30.1 months; odds ratio, 0.88, P = .007) and ARNI initiation (2.3 vs 7.2 months; odds ratio, 0.90, P = .029) to ICD implant were independently associated with latent LVRR. Cardiac magnetic resonance imaging analysis showed uniformly elevated fibrosis markers across groups, with no difference observed in native T1, T2, extracellular volume, or late gadolinium enhancement. Conventional variables, including age, sex, QRS duration, heart rate, and late gadolinium enhancement burden, were not predictive. Over a median follow-up of 33.8 months, ventricular arrhythmia incidence was comparable (9.1% vs 7.5%).
CONCLUSION: Shorter ARNI exposure before ICD implantation was independently associated with latent LVRR, highlighting the need for sufficient guideline-directed medical therapy to optimize reverse remodeling, whereas residual arrhythmic risk warrants continued ICD protection.